Other Regulatory News
Centers for Medicare and Medicaid Services (CMS)
CMS Proposes Near-Flat 2027 MA Rates, Targets Upcoding; Hospital Systems Eye Own MA Plans
CMS proposed a 0.09% net payment increase for Medicare Advantage plans in 2027, far below the 4-6% Wall Street expected. This would bar insurers from using unlinked chart reviews to inflate risk scores, a practice CMS estimates cost Medicare $7 billion in 2027 alone. Insurer stocks plunged: Humana fell 20%, UnitedHealth dropped 18%. The proposal follows a record $556 million DOJ settlement with Kaiser Permanente over improper diagnosis additions. AHIP warned of benefit cuts for 35 million seniors; Medicare Director Chris Klomp said risk adjustment reforms are necessary for program stability. Final rates are due April 6 after a February 25 comment deadline.
Meanwhile, hospital systems are increasingly launching their own Medicare Advantage plans to capture premium revenue and control care delivery costs, following a model long used by Kaiser Permanente.
Source(s):
Trump administration signals desire to curb Medicare Advantage
Medicare Advantage Insurers Face New Curbs on Overcharges
CMS proposes modest Medicare Advantage pay increase
STAT+: Trump administration proposes tiny pay raise to 2027 MA plans
Humana, UnitedHealth plunge after Trump proposes keeping MA rates flat
Medicare Advantage insurers get a 0.09% payment increase in Advance Notice
CMS proposes excluding chart reviews from MA risk scoring
Medicare Director defends MA 2027 advance notice
UnitedHealth limps into 2026 with a smaller business and fresh challenges
UnitedHealth Group shares fall 18% on MA woes
UnitedHealth Group’s earnings reflect industry-wide pressure
Politico Pulse
Trump proposal signals Medicare austerity
Why hospital-owned Medicare Advantage plans are gaining traction
Tags: #PAYER #HOSPITAL #PROVIDER
Medicare FFS Prior Auth Pilot Draws Early Provider Complaints; MA Data Shows 53M Requests in 2024
Less than a month into CMS’s WISeR pilot introducing prior authorization to fee-for-service Medicare, providers report encountering the administrative problems they warned about. Separately, KFF analysis shows MA insurers made nearly 53 million prior authorization decisions in 2024 with a 7.7% denial rate; 80.7% of appealed denials were at least partially overturned. UnitedHealth had the highest denial rate at 12.8%, Elevance the lowest at 4.2%.
Source(s):
Medicare prior authorizations off to a rocky start, providers say
53 million Medicare Advantage prior authorization requests in 2024: 6 notes
Tags: #PAYER #PROVIDER #HOSPITAL
ACA Enrollment Falls 5% to 23M After Subsidy Expiration; HCA Projects Up to $1B in Losses; Congress Scrambles
CMS reported approximately 23 million people signed up for ACA coverage for 2026, down 5% from 24.2 million. Out-of-pocket premiums more than doubled on average. Texas bucked the trend with 200,000 additional enrollees; North Carolina and Ohio saw declines of 22% and 20%. HCA Healthcare projected $600M-$900M in losses from the subsidy lapse and $250M-$450M from Medicaid supplemental payment declines.
KFF’s January 2026 tracking poll finds two-thirds of the public say Congress did the “wrong thing” not extending enhanced tax credits, including 72% of independents. Health care costs top economic concerns across partisan lines heading into midterms, with Democrats holding double-digit advantages on voter trust for Medicaid, ACA, and Medicare. Congress’s last-ditch extension efforts are underway as impacts materialize.
Source(s):
ACA enrollment backslides to 23M in 2026
ACA enrollment drops by 1M+ after subsidies expire
HCA could lose $1B from ACA subsidy lapse
KFF Health Tracking Poll: Health Care Costs, Expiring ACA Tax Credits, and the 2026 Midterms
The subsidy saga continues
Tags: #PAYER #HOSPITAL #PATIENT
CMMI Announces 10 New Payment Models Spanning Care Delivery and Drug Pricing
CMMI announced 10 new payment models in December 2025: six for care delivery (ACCESS, TEMPO, MAHA ELEVATE, LEAD, WISeR, TEAM) and four for drug pricing (GLOBE, GUARD, BALANCE, GENEROUS). ACCESS launches July 2026 with 10-year outcome-aligned payments across cardiometabolic, kidney, musculoskeletal, and behavioral health tracks. Drug pricing models tie Medicare Part B and Part D rebates to international benchmarks.
Source(s):
David Johnson: HHS launches a host of transformative payment models (Oh my!)
Tags: #HOSPITAL #PROVIDER #DRUG
CMS Finalizes Rule Restricting Medicaid Provider Tax Arrangements, Projects $78B in Federal Savings
CMS finalized a rule closing a loophole allowing seven states to levy disproportionately higher taxes on Medicaid-focused businesses to inflate federal matching funds — $8.7 billion in excess burden in 2024 alone. The rule primarily targets MCO taxes in California, Massachusetts, Michigan, and New York. CMS projects $78.2 billion in federal savings and $46.9 billion in state savings over 10 years starting in 2027. Stakeholders warned the restrictions could reduce funding for safety-net hospitals, nursing facilities, and rural systems.
Source(s):
CMS finalizes rule cracking down on Medicaid provider taxes
CMS establishes tighter limits on Medicaid tax arrangements
Tags: #HOSPITAL #PAYER
Medicaid Expansion Linked to 5% Reduction in Breast Cancer Mortality
A JAMA Network Open study of over 1.5 million women ages 40-64 found Medicaid expansion was associated with a 5% reduction in overall breast cancer mortality (HR 0.95). Hispanic women saw the greatest benefit (-19% hazard reduction). Commentators warned projected Medicaid coverage losses from the 2025 Budget Reconciliation Act could undo these gains.
Source(s):
Medicaid Expansion Linked to Lower Mortality in Breast Cancer
Tags: #PATIENT #HOSPITAL
TAVR Coverage Debate Intensifies: Edwards Seeks Medicare Expansion as Mortality Data Raises Questions
Edwards Lifesciences’ request for CMS to extend TAVR Medicare coverage to asymptomatic severe aortic stenosis patients received support from five major heart societies but pushback from individual physicians, the Society of Thoracic Surgeons, and rival Medtronic over concerns about trial generalizability and valve durability.
Separately, a study presented at the STS annual meeting found age-adjusted aortic stenosis mortality in patients ages 45-74 began climbing in 2019 after TAVR’s expansion into low-risk populations, from 3.33 to 3.57 per 100,000 by 2023. Researchers suggested shifting referral patterns may have introduced diagnostic delays.
Source(s):
Edwards’ request for broader TAVR Medicare coverage gets pushback
Aortic Stenosis Mortality Increased After Broad FDA Approval of TAVR
Tags: #DEVICE #PROVIDER #PATIENT
No Surprises Act IDR Disputes Up 40%; Providers Win 88% of Cases
Providers and insurers submitted nearly 1.2 million cases to the No Surprises Act IDR portal in the first half of 2025 — up 40% from late 2024. The top 10 initiating parties, mostly private equity-backed providers, filed nearly 70% of all disputes. Providers won 88% of resolved cases and received 3-4 times in-network rates when they won. Research estimates IDR added $5 billion in costs in its first three years.
Source(s):
No Surprises disputes increasing even as arbiters catch up, CMS says
Tags: #PAYER #PROVIDER #HOSPITAL
CMS Awards 400 New Medicare-Funded Residency Slots to 130+ Teaching Hospitals
CMS awarded 400 new Medicare-funded residency positions to over 130 teaching hospitals in December 2025, prioritizing rural areas, health professional shortage areas, and psychiatry training. At least half of the 200 Section 4122 slots are dedicated to psychiatry. The effort addresses a projected shortage of up to 86,000 physicians by 2036.
Source(s):
Hospitals awarded new Medicare-funded residency slots: A breakdown
Tags: #HOSPITAL #PROVIDER
CMS Selects 15 Drugs for Third Round of Medicare Price Negotiations, First to Include Part B Drugs
CMS announced 15 drugs for the third cycle of the Medicare Drug Price Negotiation Program, marking the first time Part B physician-administered drugs are included alongside Part D medications. Selected drugs include Biktarvy, Trulicity, Verzenio, Kisqali, Botox, and Xolair, accounting for approximately $27 billion in Medicare spending. Negotiations will occur in 2026 with prices effective January 1, 2028.
Source(s):
CMS list: 15 drugs selected for third cycle of drug negotiation program
CMS announces 15 drugs targeted for third round of Medicare price negotiations
Medicare is about to start negotiating the prices of medications administered by doctors
Tags: #DRUG #PAYER #PATIENT
Three Policy Reversals Reshape Health Care for Older Americans
CMS repealed nursing home staffing standards that would have required 3.48 hours of daily care per resident; the Labor Department rescinded 2013 rules extending minimum wage and overtime protections to home care workers; and CMS launched the WISeR prior authorization pilot in six states using AI to review Medicare claims.
Source(s):
These 3 Policy Moves Are Likely to Change Health Care for Older People
Tags: #PATIENT #HOSPITAL #PROVIDER
CMS Proposes Rules to Strengthen OPO Oversight and Expand Use of Medically Complex Organs
CMS proposed rules to strengthen oversight of Organ Procurement Organizations and maximize use of “medically complex organs” from older or sicker donors. Deceased organ donations declined last year for the first time in over a decade amid eroding public trust.
Source(s):
Less-than-perfect organs for transplant list recipients is Medicare’s latest proposal
Tags: #HOSPITAL #PATIENT
Op-Ed: CMS Should Implement Performance Measures for Public Health Data Reporting
Sheri Doyle of The Pew Charitable Trusts argues CMS should implement quantitative performance measures for public health and clinical data exchange to improve data reporting quality and interoperability.
Source(s):
CMS has the opportunity to improve public health data reporting
Tags: #ALL
Food and Drug Administration (FDA)
Gilead’s Yeztugo HIV PrEP Gains Insurer Coverage Despite $30K Annual Cost
CVS Caremark reversed its August 2025 decision and now covers Gilead’s twice-yearly HIV PrEP injection Yeztugo ($30,000/year) as of January 1, 2026. Over 85% of U.S. insurers now cover the drug. Optum Rx placed Yeztugo on tier 3 of its select formulary but excluded it from its premium formulary, citing higher net cost versus Apretude (~$22,000/year). Advocates note ongoing cost-sharing and prior authorization barriers to actual patient access.
Source(s):
6-month HIV PrEP makes coverage gains with insurers
Transformative HIV PrEP shot slowly overcomes cost hurdles
Tags: #DRUG #PAYER #PATIENT
Multi-Cancer Early Detection Tests Advance: Grail Files for FDA Approval as Medicare Coverage Provision Moves to Senate
Grail filed for FDA premarket approval of its Galleri multi-cancer early detection blood test, citing data from a 25,000-person U.S. study and a 140,000-participant U.K. trial. Grail reported preliminary 2025 Galleri revenue of $136-$137 million and forecast 22-32% growth for 2026.
The House-passed bipartisan healthcare funding package includes Medicare coverage for multi-cancer early detection screenings pending FDA clearance, with coverage beginning no earlier than January 1, 2029. The provision is now pending in the Senate. A STAT opinion piece from physicians Levy and Konety urges caution, noting concerns about the technology’s readiness for broad clinical use.
Source(s):
Grail files for FDA approval of multi-cancer early detection test
Medicare coverage for multi-cancer screenings included in funding package
Opinion: Medicare may start covering multi-cancer early detection tests
Tags: #DEVICE #PATIENT #PAYER
FDA Unveils First Official Agency Seal Marking 120 Years
FDA Commissioner Marty Makary announced the agency’s first official seal, commemorating 120 years since the 1906 Pure Food and Drugs Act.
Source(s):
FDA Unveils First Official Agency Seal
Tags: #ALL
Sanofi Abandons mRNA Seasonal Flu Vaccine Program
Sanofi shelved its mRNA seasonal flu vaccine program, two and a half years after unveiling the strategy to investors.
Source(s):
Sanofi abandons attempt to develop next-gen mRNA seasonal flu vaccine
Tags: #DRUG
CDRH on Track for Review Timelines Despite 22% Staff Reduction
The FDA’s CDRH authorized 124 novel devices in 2025 and received 21,780 submissions, both up from the prior year, despite losing approximately 22% of its workforce. The center issued 21 guidances vs. 38 in 2024 amid the deregulatory push. CDRH says it is on track to meet MDUFA V review timeline targets, though the annual report omitted workforce totals for the first time.
Source(s):
CDRH on track for review timelines despite staff cuts
Tags: #DEVICE
FDA Launches PreCheck Pilot for Domestic Drug Manufacturing; Senate Highlights Foreign Supply Chain Risks
The FDA began accepting applications for its PreCheck pilot to strengthen domestic pharmaceutical manufacturing through early technical engagement and streamlined facility assessments. A Senate Special Committee on Aging hearing highlighted that 94% of generic APIs come from India and China with limited FDA oversight. Sen. Rick Scott’s CLEAR LABELS Act would require country-of-origin labeling for drugs and APIs.
Source(s):
FDA Launches PreCheck Pilot Program
U.S. Has No Backup Plan if Foreign Generic Drugmakers Bow Out
Tags: #DRUG
Bristol Myers Squibb Bets on Cobenfy for Alzheimer’s-Related Psychosis
Bristol Myers Squibb is betting that Coben — a pill with roots in a 1990s clinical trial, rescued by Boston startup Karuna Therapeutics — can become the first approved treatment for Alzheimer’s-related psychosis. Results from three pivotal studies are expected later this year.
Source(s):
Why Bristol Myers Squibb believes a decades-old drug can treat Alzheimer’s
Tags: #DRUG
Key Medtech Trends for 2026: M&A, MDUFA VI, Surgical Robotics Competition
MedTech Dive identifies M&A, ACA subsidy expiration impacts, tariff navigation, MDUFA VI negotiations, and surgical robotics competition as key medtech trends. Boston Scientific’s $14.5 billion bid for Penumbra highlights deal activity. MDUFA VI could reach Congress for authorization this year.
Source(s):
Top medtech trends to watch in 2026
Tags: #DEVICE
First U.S. Implant of Valcare Medical’s Amend Transcatheter Mitral Device
Interventional cardiologists performed the first U.S. implant of Valcare Medical’s Amend device, a closed-ring transcatheter system designed to mimic annuloplasty rings used in open-heart surgery for mitral regurgitation.
Source(s):
Interventional cardiologists implant new-look heart device for first time in US
Tags: #DEVICE #PROVIDER
Health and Human Services
46% of CDC Surveillance Databases Paused in 2025, Study Finds
A study in Annals of Internal Medicine found 46% of CDC public health surveillance databases — 38 of 82 regularly updated records — experienced unexplained pauses as of October 2025. Of the paused databases, 87% were vaccination-related; others covered respiratory diseases and drug overdose deaths. The pauses followed a January 2025 White House directive to halt external communications. An HHS spokesperson attributed changes to “routine data quality and system management decisions.”
Source(s):
46% of CDC surveillance databases paused in 2025: Study
CDC Databases Going Without Routine Updates, Analysis Finds
Tags: #ALL
HHS Clears Path for Direct Drug Sales; Democratic Senators Question TrumpRx Legality
HHS OIG issued guidance clarifying that drug manufacturers may sell directly to Medicare and Medicaid patients at lower prices without violating the Anti-Kickback Statute, supporting the upcoming TrumpRx direct-to-consumer platform. Three Democratic senators contend TrumpRx may violate federal anti-kickback laws, citing Donald Trump Jr.’s board seat at online dispensing company BlinkRx and a 2025 investigation showing Eli Lilly and Pfizer used telehealth partners to steer patients to their products.
Source(s):
TrumpRx May Not Be Legal in Its Current Form, Senators Contend
HHS outlines path for lower-cost drugs via direct sales
Tags: #DRUG #PATIENT #PAYER
HHS Appoints 21 New Members to Federal Autism Committee; Vaccine Skeptics Prominent
HHS appointed 21 new members to the Interagency Autism Coordinating Committee, many of whom have publicly expressed belief in the debunked claim that vaccines cause autism. The reconstituted committee excludes representation from mainstream autism research organizations like Autism Speaks and the Simons Foundation. Autism researchers criticized the appointments as prioritizing MAHA allies over scientific expertise.
Source(s):
HHS appoints 21 new members to federal autism advisory committee
RFK Jr. Names 21 New Members to Federal Autism Committee
Tags: #PATIENT #PROVIDER
Research Reveals Lasting COVID-19 Health Effects as Administration Narrows Vaccine Guidance
Research shows long-term COVID-19 effects including cognitive deficits equivalent to a 3-point IQ drop in mild cases, elevated cardiovascular risk persisting nearly three years, and potential neurodevelopmental effects in children exposed in utero. The annual U.S. burden of long COVID is estimated at $9,000 per patient, with $170 billion in lost earnings. The administration has narrowed CDC vaccine recommendations to those 65+ or with risk factors and halted $500 million in mRNA vaccine funding; only 17% of U.S. adults have received the updated 2025-2026 shot.
Source(s):
Trump Policies at Odds With Emerging Understanding of Covid’s Long-Term Harm
Tags: #PATIENT #PROVIDER #DRUG
340B Covered Entities Urged to Build Data Infrastructure During Rebate Pilot Pause
Following the court-ordered pause of the 340B rebate pilot program and HHS’s decision to reconsider its approach, covered entities should use this window to build integrated data infrastructure connecting procurement, utilization, and compliance systems.
Source(s):
Data Sovereignty: The Key to Navigating 340B’s Uncertain Future
Tags: #HOSPITAL #DRUG
Measles Cases in January 2026 Already 25% of 2025 Full-Year Total
The CDC confirmed 588 measles cases in January 2026, already 25% of 2025’s full-year total of 2,267. South Carolina is hardest hit with 467 confirmed cases. An international panel is expected to decide in April whether the U.S. has lost its WHO measles elimination status, held since 2000.
Source(s):
1 month into 2026, measles cases already at 25% of 2025’s total
Tags: #ALL
Heard on the Hill
Partial Government Shutdown Begins; HHS Spending Bill Includes Telehealth Extension, PBM Reform, NIH Funding
The federal government entered a brief partial shutdown at midnight Saturday after the Senate passed a bipartisan funding deal 71-29 but the House was out of session. The deal separates DHS funding from the broader spending package, giving negotiators two weeks to resolve ICE enforcement debates linked to the fatal shootings of two U.S. citizens by federal immigration agents in Minneapolis.
The HHS appropriations bill passed by the Senate includes a two-year Medicare telehealth extension, health extenders, PBM reform provisions, and increased NIH funding. The House must vote again this week due to changes in the broader deal.
Source(s):
Another government shutdown has started, but a Senate breakthrough means it may be brief
Senate leaders scramble to save bipartisan deal
Senate Passes HHS Approps Bill, Including Two-Year Telehealth, Other Health Extenders, PBM Reform
HHS spending bill caught up in ICE debate
Congress Can Make Shutdowns a Thing of the Past
Tags: #ALL
Medicaid PBM Spread Pricing Ban Stalled by CBO Score
A bipartisan bill to prohibit PBMs from using spread pricing in Medicaid managed care contracts is stalled due to its CBO score and likely won’t advance until the lame duck session following the 2026 midterm elections.
Source(s):
Medicaid PBM Spread Pricing Bill Reportedly Hung Up By CBO Score
Tags: #DRUG #PAYER
E&C Republicans Set Medicare, Medicaid Fraud Hearing
House Energy & Commerce Committee Republicans will hold a hearing on Medicare and Medicaid fraud as part of a broader GOP campaign targeting alleged waste, fraud, and abuse in Democrat-led states.
Source(s):
E&C Republicans Set Medicare, Medicaid Fraud Hearing Amid Broader GOP Push
Tags: #ALL
KFF Poll: Health Care Costs Top Public Economic Worries Heading Into Midterms
A KFF poll finds 32% of the public is “very worried” about affording health care — more than food (24%), housing (23%), or utilities (22%). Over 4 in 10 voters say health care costs will have a major impact on their 2026 midterm vote. Independent voters trust Democrats over Republicans on health care costs by a 35%-15% margin.
Source(s):
Health Care Costs Tops the Public’s Economic Worries
Tags: #ALL
RFK Jr. Supporters Target Sen. Cassidy After HHS Oversight Questioning
Supporters of HHS Secretary Robert F. Kennedy Jr.’s Make America Healthy Again movement say they oppose Sen. Bill Cassidy’s reelection after the Louisiana Republican questioned Kennedy during oversight proceedings.
Source(s):
Cassidy questioned RFK Jr. Now Kennedy’s followers are out to get him.
Tags: #ALL
Notable Notes
KFF Poll: Prior Authorization Is the Top Burden for Insured Adults
A KFF poll of 1,426 adults found 32% of insured adults call prior authorization a “major burden” — more than understanding bills (23%) or getting timely appointments (20%). Among those with chronic conditions, 39% ranked it the single biggest barrier. About half of insured adults reported a service denied, delayed, or altered by their insurer in the past two years.
Source(s):
Poll: People View Prior Authorization as Greatest Burden
Tags: #ALL
AI Model Turns POCUS Images Into Structural Heart Evaluations
Researchers developed an AI model that converts point-of-care ultrasound images into accurate structural heart evaluations, potentially enabling non-cardiologists to perform cardiac screening more easily.
Source(s):
AI model turns POCUS images into accurate structural heart evaluations
Tags: #DEVICE #PROVIDER
Medtech M&A Reached $80B in 2025, Surpassing Prior Three Years
Medical device M&A reached approximately $80 billion through November 2025, according to Bain & Company. Major deals included Abbott’s planned $21 billion acquisition of Exact Sciences and Hologic’s $18.3 billion go-private transaction. Spinoffs and divestitures accounted for $27 billion, roughly one-third of total deal value.
Source(s):
Medtech M&A took off in the second half of 2025: report
Tags: #DEVICE
Hospital-Based Anesthesia and Radiology: A Broken Financial Model
Hospital subsidies for anesthesia range from $10,000-$30,000 per bed and radiology $5,000-$15,000 per bed, driven by Medicare underpayment (~$22/ASA unit vs. $80.70 commercial average). Nearly 80% of facilities reported anesthesiologist shortages in 2022, up from 38% in 2020; 81% of rural counties have no anesthesiologist. Private equity now owns 33% of anesthesiology and 12% of radiology practices.
Source(s):
Hospital-based anesthesia and radiology: A broken financial model
Tags: #HOSPITAL #PROVIDER
Labor Department Proposes PBM Compensation Disclosure Rule for Self-Insured Plans
The Department of Labor proposed a rule requiring PBMs to disclose rebates, manufacturer fees, spread pricing compensation, and recouped pharmacy payments to self-insured group health plan sponsors. PBMs would also have to reveal which formulary drugs are included due to manufacturer compensation and disclose conflicts of interest in step therapy protocols. Plan fiduciaries gain audit rights with civil penalties for noncompliance. The rule applies only to self-insured plans (~9.5 million people) and has a notable gap: PBM-affiliated group purchasing organizations could retain rebate slices. The 60-day comment period opened January 30.
Source(s):
Labor Department wants to strong-arm PBMs into being more transparent with employers
Labor Department proposes PBM compensation disclosure rule for self-insured plans
Tags: #DRUG #PAYER
GAO Releases FY 2025 Performance and Accountability Report
GAO released its FY 2025 Performance and Accountability Report, detailing accomplishments, performance measures, financial statements, and management challenges.
Source(s):
Performance and Accountability Report, Fiscal Year 2025
Tags: #ALL
Cigna Identifies Five Employer Health Care Trends for 2026
Cigna Healthcare identifies escalating care costs (8.2% expenditure growth in 2024), pharmacy cost pressures (32% of total spend), benefits as retention leverage, demand for digital health, and clinical breakthroughs including GLP-1 expansion and AI adoption (66% of physicians now use AI tools) as key employer trends. Integrated pharmacy-medical benefits can save $241/member/year.
Source(s):
The top health care trends for 2026
Tags: #PAYER #HOSPITAL
Standalone Cardiology Certification Board Effort Continues
The American Board of Cardiovascular Medicine continues efforts to create a standalone cardiology certification board, exploring partnerships after its initial application was not approved.
Source(s):
The fight for modernized cardiologist certification is still alive
Tags: #PROVIDER
Vox: Conditions Ripening for Next Major Health Care Reform Push
Vox analysis argues that despite Congress failing to extend ACA subsidies, conditions are ripening for another major health care reform push. Nearly two-thirds of Americans believe the government should guarantee health coverage. The piece cites shifting AMA positions on single-payer, state-level public option experiments, and bipartisan PBM reform efforts as evidence.
Source(s):
There’s a silver lining to our health care cost crisis
Tags: #ALL
Joint Commission Launches New Cardiac Care Certification with STS and ACC
The Joint Commission announced a cardiac care certification developed with the Society of Thoracic Surgeons and American College of Cardiology, focused on quality of care and patient outcomes. The certification uses data from the STS Adult Cardiac Surgery Database, ACC CathPCI Registry, or STS/ACC TVT Registry.
Source(s):
Joint Commission partners with STS, ACC on new cardiac care certification
Tags: #HOSPITAL #PROVIDER